What are the typical symptoms and management plan for a patient with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) class II-IV symptoms?

Symptoms and Management of NYHA Class II-IV Heart Failure with Reduced Ejection Fraction

Typical Symptoms

Patients with NYHA class II-IV HFrEF present with dyspnea and fatigue that progressively limit physical activity, along with signs of fluid retention including peripheral edema and pulmonary rales. 1

Symptom Severity by NYHA Class:

• NYHA Class II: Slight limitation of physical activity; comfortable at rest, but ordinary physical activity (walking, climbing stairs) results in dyspnea, fatigue, or palpitations 1
• NYHA Class III: Marked limitation of physical activity; comfortable at rest, but less-than-ordinary activity causes symptoms 1
• NYHA Class IV: Unable to carry out any physical activity without symptoms, or symptoms present at rest 1

Critical Clinical Pitfall:

Symptom severity correlates poorly with ventricular function and ejection fraction—patients with very low LVEF may be asymptomatic while those with preserved LVEF may have severe disability. 1, 2 Additionally, symptoms can fluctuate rapidly; a stable NYHA class II patient can deteriorate to class IV with onset of arrhythmia, and an acutely decompensated class IV patient may improve dramatically with diuretics. 1

Physical Examination Findings:

• Congestion signs: Peripheral edema, jugular venous distension, pulmonary rales, hepatomegaly 1
• Perfusion signs: Cool extremities, narrow pulse pressure, altered mental status in advanced cases 1
• Important caveat: Signs may be absent in early HF or in patients already treated with diuretics 1

---

Management Plan: Foundational Quadruple Therapy

All patients with symptomatic HFrEF (NYHA II-IV) should receive four foundational medication classes initiated simultaneously as soon as possible after diagnosis, providing approximately 73% mortality reduction over 2 years. 3

Step 1: Initiate All Four Medication Classes Together

Start these medications concurrently, not sequentially: 3

1. SGLT2 Inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily)

   • Reduces cardiovascular death and HF hospitalization regardless of diabetes status 3
   • Minimal blood pressure effect (only -1.50 mmHg in patients with baseline SBP 95-110 mmHg) 3
   • Should be started first along with MRA 3

2. Mineralocorticoid Receptor Antagonist (spironolactone 12.5-25 mg daily or eplerenone 25 mg daily)

   • Provides at least 20% mortality reduction and reduces sudden cardiac death 3
   • Minimal blood pressure effect, allowing early initiation 3
   • Requires monitoring of potassium (keep <5.5 mEq/L) and creatinine 3

3. Beta-Blocker (carvedilol, metoprolol succinate, or bisoprolol)

   • Reduces mortality by at least 20% and decreases sudden cardiac death 3, 4
   • Start at low dose: carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily, or bisoprolol 1.25 mg daily 5
   • Evidence-based agents only—avoid atenolol or metoprolol tartrate 5

4. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) - sacubitril/valsartan

   • Preferred over ACE inhibitors, providing superior mortality reduction of at least 20% 3, 6
   • Start at 24/26 mg twice daily (or 49/51 mg twice daily if previously on moderate-dose ACE inhibitor/ARB) 5, 6
   • Must wait 36 hours after stopping ACE inhibitor before starting ARNI to avoid angioedema 5
   • If ARNI not tolerated, use ACE inhibitor (enalapril, lisinopril, ramipril) or ARB (losartan, valsartan) 3

Step 2: Diuretics for Volume Management

Loop diuretics are essential for congestion control but do not reduce mortality: 3

• Furosemide 20-40 mg once or twice daily
• Torsemide 10-20 mg once daily
• Bumetanide 0.5-1.0 mg once or twice daily 3

Titrate diuretic dose to achieve euvolemia (no edema, no orthopnea, no jugular venous distension), then use the lowest dose that maintains this state. 1, 5

Step 3: Titration Strategy

Up-titrate one drug at a time every 1-2 weeks using small increments until target or maximally tolerated dose is achieved: 3

Titration sequence: 3

1. Start SGLT2 inhibitor and MRA first (minimal BP effect)
2. Then add beta-blocker if heart rate >70 bpm
3. Finally add ARNI or ACE inhibitor/ARB at low dose

Target doses proven in clinical trials: 5

• Sacubitril/valsartan: 97/103 mg twice daily
• Carvedilol: 25-50 mg twice daily
• Metoprolol succinate: 200 mg daily
• Bisoprolol: 10 mg daily
• Spironolactone: 25-50 mg daily
• Enalapril: 10-20 mg twice daily

---

Special Considerations for NYHA Class III-IV Patients

Additional Therapy for Self-Identified Black Patients:

Hydralazine/isosorbide dinitrate is indicated for Black patients with NYHA class III-IV symptoms despite optimal therapy: 3

• Start hydralazine 25 mg three times daily + isosorbide dinitrate 20 mg three times daily
• Target dose: hydralazine 75 mg three times daily + isosorbide dinitrate 40 mg three times daily 3

Ivabradine for Persistent Tachycardia:

Consider if heart rate ≥70 bpm in sinus rhythm despite maximally tolerated beta-blocker: 3

• Start 2.5-5 mg twice daily, target 7.5 mg twice daily 3
• Note: Survival benefit is modest or negligible in the broad HFrEF population 3

Device Therapy Indications:

Implantable Cardioverter-Defibrillator (ICD): 5, 3

• Indicated for NYHA class II-III with LVEF ≤35% despite ≥3 months of optimal medical therapy
• Expected survival >1 year with good functional status
• Do NOT implant within 40 days of myocardial infarction—no benefit during this period 5

Cardiac Resynchronization Therapy (CRT): 5, 3

• Indicated for symptomatic patients in sinus rhythm with:
  • QRS ≥150 msec AND left bundle branch block (LBBB) morphology
  • LVEF ≤35% despite optimal medical therapy 5

---

Management of Low Blood Pressure

Do not withhold or down-titrate GDMT for asymptomatic low blood pressure with adequate perfusion (warm extremities, normal mentation, adequate urine output). 3

Algorithm for Hypotension:

If SBP <80 mmHg or symptomatic hypotension: 3

1. First, evaluate for reversible non-HF causes:

   • Alpha-blockers (tamsulosin, doxazosin)—STOP these medications 3
   • Excessive diuresis—reduce diuretic dose 3
   • Other vasodilators (nitrates, calcium channel blockers)—discontinue 3

2. Start SGLT2 inhibitor and MRA first (minimal BP effect) 3

3. Then add very low-dose beta-blocker or ARNI 3

GDMT medications have proven efficacy and safety even in patients with baseline SBP <110 mmHg. 3

---

Medications to AVOID in HFrEF

These medications worsen outcomes and should be discontinued: 5, 3

• Diltiazem or verapamil: Increase risk of worsening HF and hospitalization 5, 3
• Triple combination of ACE inhibitor + ARB + MRA: Causes life-threatening hyperkalemia and renal dysfunction 5, 3
• ACE inhibitor combined with ARNI: Risk of angioedema 3
• Alpha-blockers (tamsulosin, doxazosin): Interfere with GDMT optimization by causing hypotension 3
• NSAIDs: Cause sodium retention and worsen congestion 5

---

Monitoring Requirements

Check at each medication adjustment: 5

• Blood pressure
• Heart rate
• Renal function (creatinine, eGFR)
• Electrolytes (potassium, sodium)

Monitoring schedule: 5

• Baseline before starting medications
• 1-2 weeks after each dose adjustment
• At 3 months after achieving stable doses
• Then every 6 months indefinitely

Acceptable parameters during titration: 3

• Potassium up to 5.5 mEq/L is acceptable (do not stop MRA unless >5.5)
• Creatinine increase up to 30% from baseline is acceptable
• Asymptomatic SBP >90 mmHg is acceptable—continue titration

---

Common Pitfalls to Avoid

1. Delaying initiation of all four medication classes—start simultaneously, not sequentially 3
2. Accepting suboptimal doses—always attempt to reach target doses proven in trials 3
3. Stopping medications for asymptomatic hypotension—adverse events occur in 75-85% of HFrEF patients regardless of treatment 3
4. Using non-evidence-based beta-blockers (atenolol, metoprolol tartrate)—only use carvedilol, metoprolol succinate, or bisoprolol 5
5. Inadequate monitoring—check labs 1-2 weeks after each adjustment 5
6. Ignoring NYHA class II patients—approximately half of HFrEF patients have only mild symptoms but remain at high risk of hospitalization and death 7, 8